United Therapeutics Corporation Earnings

United Therapeutics Corporation’s revenue jumped 11.71% since last year same period to $798.6Mn in the Q2 2025. On a quarterly growth basis, United Therapeutics Corporation has generated 0.53% jump in its revenue since last 3-months.

United Therapeutics Corporation’s net profit jumped 11.29% since last year same period to $309.5Mn in the Q2 2025. On a quarterly growth basis, United Therapeutics Corporation has generated -3.94% fall in its net profits since last 3-months.

United Therapeutics Corporation’s net profit margin fell -0.37% since last year same period to 38.76% in the Q2 2025. On a quarterly growth basis, United Therapeutics Corporation has generated -4.45% fall in its net profit margins since last 3-months.

United Therapeutics Corporation’s price-to-earnings ratio after this Q2 2025 earnings stands at 12.22.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current quarter stand at 7.4 - a 0.68% jump from last quarter’s estimates.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current year stand at 7.4.

United Therapeutics Corporation’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the United Therapeutics Corporation has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.